Home
Life Sciences

Sector: Life Sciences

Trade secret litigation soars in the life sciences industry

Trade secrets surge ahead in the age of the DTSA due to evolving IP terrain and rising patent litigation risks

Does the impact of Markman orders vary by technology complexity?

Some patent litigators observe that patent disputes involving less complicated technologies tend to settle faster after claim construction. What does Docket Navigator data say?

Life Sciences correspondent

Thought leadership from industry experts

Latest updates

EPO Enlarged Board of Appeal confirms use of post-published data to support inventive step

Latest content

Janssen secures yet more patent settlements with Stelara biosimilars

Here are six key takeaways for patent strategists from the succession of ustekinumab settlements

05 September 2023

Surging litigation numbers and public distrust plague life sciences landscape

From trade secrets to overregulation, there are many core threats to the global life sciences arena. But expert advice outlines strategic ways to neutralise them

05 September 2023

US appeal court antitrust decision is good news for patent licensing

The judgment over an agreement between Endo Pharmaceuticals and Impax Laboratories comes against a backdrop of increasing FTC interest in IP strategies

01 September 2023

USPTO director takes greater control of agency’s post-grant proceedings

Kathi Vidal’s recent director review rulings of PTAB institution decisions – following new agency guidelines – shows that her aggressive approach to review is intensifying

30 August 2023

Moderna jab does not infringe Alnylam mRNA patents, finds US court

Meanwhile, Pfizer/BioNTech are taking aim at two Moderna patents

30 August 2023

‘We want to de-risk the CRISPR-Cas9 patent minefield’, says Sigma-Aldrich IP licensing boss

IAM speaks exclusively to Christopher Arnot about the crowded CRISPR IP landscape

25 August 2023

Patent linkage in China: what the first decisions reveal about the direction of travel

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

The first decisions issued since China’s patent-linkage system’s implementation indicate that patentees should take full advantage; litigation is faster and patentees are relieved of key burdens. However, preparation is critical and making the right choice between the civil action and administrative adjudication routes is imperative.

25 August 2023

Mexico’s patent linkage system and allopathic medicines

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Following an IP law reform introduced to combat confusion around allopathic medicines, IMPI and COFEPRIS are legally bound to cooperate. However, a new opposition process has thrust Mexico's patent linkage regime into the spotlight once again.

25 August 2023

How to take advantage of both EPO prosecution and German enforcement

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

The majority of patents in the life sciences sector are filed with the EPO and not the German Patent and Trademark Office, however, when it comes to enforcement, Germany has long been a preferred venue for rights holders.

25 August 2023

India: the pharmacy of the world and its patent landscape

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

Launching products in the Indian market requires comprehensive strategies to navigate the complex legal and regulatory landscape. One cannot extend the term of patent protection using supplementary protection certificates or patent term adjustments, so it is crucial to take proactive measures to secure a longer enforceable protection period.

25 August 2023

Unlock unlimited access to all IAM content